This unique HER2 scoring model did not rely on challenging manual intervention and proved to be a simple and robust tool for pathologists to improve the accuracy of HER2 interpretation and provided a clinical aid to target therapy in breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.